Flagship unveils Cygnal, a nervy take on cancer, inflammation
Flagship’s Cygnal is deploying $65M to drug neurological drivers of cancer, inflammation
Cygnal Therapeutics Inc. believes overlooked corners of neurobiology could unlock therapeutic strategies in cancer, inflammation and beyond. With $65 million from Flagship Pioneering and other undisclosed investors, the company launched Tuesday to advance two candidates discovered via its “exoneural biology” platform.
The company’s founding thesis is that the nervous system, particularly the peripheral nervous system (PNS), contributes to the pathology of a much wider range of diseases than those traditionally